Search Result

Isoforms Recommended:	Lck

Results for "

LCK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (21) Aurora Kinase (1) Autophagy (7) Bcr-Abl (8) BCRP (1) Biochemical Assay Reagents (1) BMX Kinase (1) Btk (5) c-Fms (3) c-Kit (11) c-Met/HGFR (2) Caspase (1) CD3 (1) Checkpoint Kinase (Chk) (1) Discoidin Domain Receptor (2) EGFR (4) Ephrin Receptor (4) ERK (4) FAK (3) FGFR (9) FLT3 (13) Fluorescent Dye (1) Fungal (1) GSK-3 (1) HSP (2) IFNAR (1) Insulin Receptor (1) Interleukin Related (3) Itk (1) JAK (3) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) LRRK2 (1) MAP3K (1) MAP4K (4) MHC (1) Mitophagy (4) MNK (1) Molecular Glues (4) Organoid (4) p38 MAPK (10) PDGFR (12) Phosphatase (3) Pim (1) PKC (2) PROTACs (3) Pyk2 (1) Raf (1) Reference Standards (15) Ribosomal S6 Kinase (RSK) (1) Small Interfering RNA (siRNA) (3) Src (73) Syk (11) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (1) Tie (1) TNF Receptor (2) Transmembrane Glycoprotein (1) Trk Receptor (1) Tyrosinase (1) VEGFR (11) γ-secretase (1)
By Research Areas:	Cancer (82) Cardiovascular Disease (4) Infection (2) Inflammation/Immunology (43) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

116

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10256

Adezmapimod Maximum Cited Publications 601 Publications Verification SB 203580; RWJ 64809	Organoid p38 MAPK Autophagy Mitophagy HSP	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-13805

PP2 60+ Cited Publications AGL 1879	Src	Cancer
PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC₅₀s of 4 and 5 nM for *Lck* and Fyn, respectively.

HY-10234

Saracatinib 35+ Cited Publications AZD0530	Src Autophagy	Cancer
Saracatinib (AZD0530) is a potent Src family inhibitor with IC₅₀s of 2.7 to 11 nM for c-Src, *Lck, c-YES, Lyn, Fyn, Fgr, and Blk*. Saracatinib shows high selectivity over other tyrosine kinases .

HY-13038A

Fostamatinib 10+ Cited Publications R788	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-12067

R406 35+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-10256A

Adezmapimod hydrochloride Maximum Cited Publications 601 Publications Verification SB 203580 hydrochloride; RWJ 64809 hydrochloride	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-10209

Masitinib 5+ Cited Publications AB1010	c-Kit PDGFR Src FGFR FAK Apoptosis	Cancer
Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), *Lck, and, to a lesser extent, FGFR3* and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-12299

WH-4-023 5 Publications Verification Dual LCK/SRC inhibitor	Src	Cancer
WH-4-023 is a potent and selective dual *Lck/Src* inhibitor with IC₅₀ of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

HY-101053

Src Inhibitor 1 15+ Cited Publications Src Kinase Inhibitor 1; Src-l1	Src	Cancer
Src Inhibitor 1 is a potent, ATP-competitive and selective dual site Src tyrosine kinase inhibitor with IC₅₀ values of 44 nM for Src and 88nM for Lck.

HY-10209A

Masitinib mesylate 5+ Cited Publications AB-1010 mesylate	c-Kit PDGFR Src FGFR Apoptosis	Cancer
Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), *Lck, and, to a lesser extent, FGFR3* and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-13804

PP1 10+ Cited Publications AGL 1872; EI 275	Src Apoptosis	Cancer
PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC₅₀ of 5 and 6 nM for Lck and Fyn, respectively.

HY-15764

A 419259 5+ Cited Publications RK-20449	Src Apoptosis	Cancer
A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, has high selectivity towards the Src family. A 419259 shows inhibitory effect for Src, *Lck* and Lyn with IC₅₀ of 9 nM, <3 nM and <3 nM, respectively .

HY-132166

Velzatinib 1 Publications Verification M4205; IDRX-42	c-Kit PDGFR c-Fms FLT3 Src	Cancer
Velzatinib (M4205) is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, c-Kit, FLT3, and *LCK, with an IC₅₀*s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. Velzatinib exhibits antitumor efficacy in xenograft mouse models .

HY-12076

BMS 777607 10+ Cited Publications BMS 817378	c-Met/HGFR TAM Receptor	Cancer
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC₅₀s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases .

HY-13038

Fostamatinib Disodium 10+ Cited Publications R788Disodium	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-15196

TAK-285 3 Publications Verification	EGFR	Cancer
TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC₅₀ of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .

HY-15764A

A 419259 trihydrochloride 5+ Cited Publications RK 20449 trihydrochloride	Src Apoptosis	Cancer
A 419259 trihydrochloride is a Src family kinases inhibitor with IC₅₀s of 9 nM, 3 nM and 3 nM for Src, *Lck* and Lyn, respectively .

HY-11108

R406 free base 35+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-10251

BMS-599626 3 Publications Verification AC480	EGFR	Cancer
BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-12072

Lck Inhibitor 3 Publications Verification	Src	Inflammation/Immunology
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC₅₀s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis .

HY-W062835

CGP77675	Src	Cancer
CGP77675 is an orally active and potent inhibitor of Src family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀s of 5-20 and 40 nM, respectively), and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity .

HY-108318

RK-24466 1 Publications Verification KIN 001-51	Src	Cardiovascular Disease Inflammation/Immunology
RK-24466 (KIN 001-51) is a potent and selective *Lck* inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC₅₀s of less than 1 and 2 nM, respectively.

HY-11011

A-770041 5+ Cited Publications	Src	Inflammation/Immunology
A-770041 is a selective and orally active Src-family *Lck* inhibitor. A-770041 inhibits Lck with an IC₅₀ value of 147 nM with the presence of 1 mM ATP. A-770041 shows 300-fold selective to Lck over Fyn, the other Src family kinase involved in T-cell signaling. A-770041 can be used for the research of acute rejection .

HY-15590

AZ-23 3 Publications Verification AZD1332	Trk Receptor	Cancer
AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC₅₀s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

HY-13038B

Fostamatinib disodium hexahydrate 10+ Cited Publications R788 disodium hexahydrate	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-10204

OSI-930 4 Publications Verification	c-Kit VEGFR c-Fms Apoptosis	Cancer
OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC₅₀s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, *Lck* and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .

HY-10644

Lck inhibitor 2	Src	Inflammation/Immunology
Lck inhibitor 2 is a multi-target tyrosine kinase inhibitor with IC50s of 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

HY-P3279

EPQpYEEIPIYL 1 Publications Verification	Src	Cancer
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .

HY-108485

Damnacanthal	Src Apoptosis Fungal	Infection Inflammation/Immunology Cancer
Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of p56 ^lck tyrosine kinase activity. Natural Damnacanthal inhibits p56 ^lck autophosphorylation and phosphorylation of exogenous substrates with IC₅₀s of 46 nM and 220 nM, respectively. Damnacanthal is a potent inducer of apoptosis with anticancer activity. Damnacanthal also has antinociceptive, anti-inflammatory effects in mice and anti-fungal activity against *Candida albicans* .

HY-10185

TG 100572 Hydrochloride 3 Publications Verification	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-12010

BMS-599626 Hydrochloride 3 Publications Verification AC480 Hydrochloride	EGFR	Cancer
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-12847

CCT241161	Raf Src Apoptosis	Cancer
CCT241161 is an orally active pan-RAF inhibitor with IC₅₀s of 3, 6, 10, 15 and 30 nM for *LCK, CRAF, SRC, V600E-BRAF* and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity .

HY-18302

c-Kit-IN-5-1 1 Publications Verification	c-Kit	Inflammation/Immunology
c-Kit-IN-5 is potent inhibitor of c-Kit, with IC₅₀s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties .

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, *Lck, Lyn, Src, Yes*, respectively.

HY-10234A

Saracatinib difumarate 35+ Cited Publications AZD0530 difumarate	Src	Cancer
Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-112291

SB 220025	p38 MAPK Src PKC	Inflammation/Immunology
SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC₅₀ = 60 nM). SB 220025 also inhibits p56 ^Lck and PKC with IC₅₀ values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation .

HY-10256R

Adezmapimod (Standard) SB 203580 (Standard); RWJ 64809 (Standard)	Organoid Reference Standards p38 MAPK Autophagy Mitophagy HSP	Inflammation/Immunology Cancer
Adezmapimod (Standard) is the analytical standard of Adezmapimod. This product is intended for research and analytical applications. Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-175280

Lck degrader-1	Molecular Glues Src	Cancer
Lck degrader-1 (Compound 17) is a molecular glue degrader targeting lymphocyte-specific protein tyrosine kinase (LCK) (DC₅₀=23.1 nM). Lck degrader-1 is promising for research of T-cell acute lymphoblastic leukemia (T-ALL) .

HY-175463

LCK degrader-2	Molecular Glues Src	Cancer
LCK degrader-2 (Compound 17) is a *Lck* Molecular glue degrader. LCK degrader-2 can be used for cancers like acute lymphoblastic leukemia (ALL) research .

HY-178120

Lck-IN-4	Src Apoptosis	Cancer
Lck-IN-4 (Compound A-1) is a protein tyrosine kinase *Lck* inhibitor with an IC₅₀ of 2  nM. Lck-IN-4 significantly inhibits YAP tyrosine phosphorylation and activity and induces apoptosis in cholangiocarcinoma CCA cells. Lck-IN-4 is cytotoxic in CCA tumor-derived organoids with elevated YAP activity Lck-IN-4 can be used for cancers like cholangiocarcinoma (CCA) research .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against *LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-175281

SJ11646	PROTACs Src Discoidin Domain Receptor Bcr-Abl Apoptosis	Cancer
SJ11646 is a Dasatinib (HY-10181)-based *LCK* PROTAC degrader with a DC₅₀ of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)

HY-10256AR

Adezmapimod hydrochloride (Standard) SB 203580 hydrochloride (Standard); RWJ 64809 hydrochloride (Standard)	Organoid Reference Standards p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (hydrochloride) (Standard) is the analytical standard of Adezmapimod (hydrochloride). This product is intended for research and analytical applications. Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-175437

MRT-7612	Molecular Glues Src Bcr-Abl	Inflammation/Immunology Cancer
MRT-7612 (Compound 4) is a cereblon-based tyrosine kinases molecular glue degrader. MRT-7612 significantly induces HCK and LYN degradation, with week efficacy on *LCK*. MRT-7612 can be used for cancers like chronic myeloid leukemia, autoimmune and chronic inflammatory diseases research .

HY-P1377A

Caffeic acid-pYEEIE TFA 1 Publications Verification	Src	Neurological Disease Inflammation/Immunology Cancer
Caffeic acid-pYEEIE TFA, a phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

HY-162676

SJ45566	PROTACs Src	Cancer
SJ45566 a potent and orally active PROTAC-based *LCK* degrader, with a DC₅₀ of 1.21 nM. SJ45566 can be used in the research for T‑Cell Acute Lymphoblastic Leukemia .

HY-15764G

A 419259 RK-20449	Src Apoptosis	Cancer
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC₅₀s of 9 nM, <3 nM, and <3 nM, respectively .

HY-18307

SYN1143	c-Met/HGFR	Cancer
SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on *Lck, Tie2, Src, and BTK* with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated .

Cat. No.	Product Name	Type

HY-15764G

A 419259 RK-20449	Fluorescent Dye
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC₅₀s of 9 nM, <3 nM, and <3 nM, respectively .

HY-D3058

*FITC-amide-C2 Lck* inhibitor 2**	Fluorescent Dye
FITC-amide-C2 Lck inhibitor 2 is a FITC-labeled *Lck* inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P3279

EPQpYEEIPIYL 1 Publications Verification	Src	Cancer
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P1377A

Caffeic acid-pYEEIE TFA 1 Publications Verification	Src	Neurological Disease Inflammation/Immunology Cancer
Caffeic acid-pYEEIE TFA, a phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

HY-P1377

Caffeic acid-pYEEIE	Src	Inflammation/Immunology
Caffeic acid-pYEEIE, a phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99129

Anti-Mouse CD8a Antibody (53-6.7) 3 Publications Verification	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108485

Damnacanthal	Infection Quinones Monophenols Classification of Application Fields Anthraquinones Morinda citrifolia Linn. Rubiaceae Phenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Src Apoptosis Fungal
Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of p56 ^lck tyrosine kinase activity. Natural Damnacanthal inhibits p56 ^lck autophosphorylation and phosphorylation of exogenous substrates with IC₅₀s of 46 nM and 220 nM, respectively. Damnacanthal is a potent inducer of apoptosis with anticancer activity. Damnacanthal also has antinociceptive, anti-inflammatory effects in mice and anti-fungal activity against *Candida albicans* .

HY-N12166

2,3,4,6,8-Pentahydroxy-1-methylxanthone	Cardiovascular Disease Structural Classification Flavonoids Microorganisms Classification of Application Fields Marine natural products Other Flavonoids Marine microorganism Disease Research Fields Source Classification	Src
2,3,4,6,8-Pentahydroxy-1-methylxanthone is a xanthone derivative of Wardomyces anomalus. 2,3,4,6,8-Pentahydroxy-1-methylxanthone shows significant antioxidant activities. 2,3,4,6,8-Pentahydroxy-1-methylxanthone is inhibitors of p56lck tyrosine kinase. 2,3,4,6,8-Pentahydroxy-1-methylxanthone can be used to research cardiovascular disease .

Species:	Human (3)
Tag:	Tag Free (1) Avi (1) GST (1)
Source:	Sf9 insect cells (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702723

	Lck Protein, Human (Active, Biotinylated, sf9, Avi) Tyrosine-protein kinase LCK; LSK; LCK; Hck-3	Human	Sf9 insect cells
	The Lck protein is a non-receptor tyrosine protein kinase that is essential for T cell development and function. Lck is constitutively associated with CD4 and CD8 receptors and is recruited to the TCR/CD3 complex following TCR interaction with MHC. Lck Protein, Human (Biotinylated, sf9, Avi) is the recombinant human-derived Lck, expressed by Sf9 insect cells, with Avi labeled tag.

HY-P73269

	Lck Protein, Human (Active, sf9, GST) Tyrosine-protein kinase LCK; LSK; LCK; Hck-3	Human	Sf9 insect cells
	The Lck protein is a non-receptor tyrosine protein kinase that is essential for T cell development and function. Lck is constitutively associated with CD4 and CD8 receptors and is recruited to the TCR/CD3 complex following TCR interaction with MHC. Lck Protein, Human (sf9, GST) is the recombinant human-derived Lck protein, expressed by Sf9 insect cells , with N-GST labeled tag.

HY-P705567

	Lck Protein, Human (sf9) Tyrosine-protein kinase LCK; Leukocyte C-terminal Src kinase (LSK); Lymphocyte cell-specific protein-tyrosine kinase; Protein YT16; Proto-oncogene LCK; T cell-specific protein-tyrosine kinase; p56-LCK	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (8) Rabbit (4)
Reactivity:	Human (12) Rat (3) Mouse (3)
Application:	IHC-P (2) ICC/IF (4) IF-Tissue (1) IP (2) IHC-F (1) WB (12) FC (2) ELISA (4)
Isotype:	IgG (2) IgG1 (5) IgG2a (2) IgG/Kappa (1)
Conjugation:	Non-conjugated (12) Biotin (1)
Clonality:	Monoclonal (7) Monoclonal Antibody (1) Recombinant (2)
Modification:	Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86477

	Lck Antibody (YA6169) LCK; Tyrosine-protein kinase LCK; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell-specific protein-tyrosine kinase; Protein YT16; Proto-oncogene LCK; T cell-specific protein-tyrosine kinase; p56-LCK	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Lck Antibody (YA6169) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lck.

HY-P85255

	Lck Antibody (YA4947) LCK; Tyrosine-protein kinase LCK; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell-specific protein-tyrosine kinase; Protein YT16; Proto-oncogene LCK; T cell-specific protein-tyrosine kinase; p56-LCK	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, IP, FC	Human
	Lck Antibody (YA4947) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Lck.

HY-P85555

	Lck Antibody (YA5247) LCK; LCK p56; LCK_HUMAN; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell specific protein tyrosine kinase; Lymphocyte cell-specific protein-tyrosine kinase; Lymphocyte Specific Protein Tyrosine Kinase; Membrane associated protein tyrosine kinase; Oncogene LCK; P56 LCK; p56; LSTRA; protein tyrosine kinase; p56-LCK; p56LCK; pp58 LCK; pp58LCK; Protein YT16; Proto oncogene tyrosine protein kinase LCK; Proto-oncogene LCK; Protooncogene tyrosine protein kinase LCK; T cell specific protein tyrosine kinase; T cell-specific protein-tyrosine kinase; T lymphocyte specific protein tyrosine kinase p56LCK; Tyrosine-protein kinase LCK; YT 16; YT16.	WB	Human
	Lck Antibody (YA5247) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Lck.

HY-P83970

	Lck Antibody (YA3667) YT16; p56LCK; pp58LCK	WB, ELISA	Human
	Lck Antibody (YA3667) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Lck.

HY-P83970A

	Lck Antibody (YA3667)(PBS only) YT16; p56LCK; pp58LCK	WB, ELISA	Human
	Lck Antibody (YA3667) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Lck.

HY-P80743

	Lck Antibody (YA712) LCK; Tyrosine-protein kinase LCK; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell-specific protein-tyrosine kinase; Protein YT16; Proto-oncogene LCK; T cell-specific protein-tyrosine kinase; p56-LCK	WB	Human
	Lck Antibody (YA712) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lck.

HY-P80743A

	Lck Antibody (YA712)(PBS only) LCK; Tyrosine-protein kinase LCK; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell-specific protein-tyrosine kinase; Protein YT16; Proto-oncogene LCK; T cell-specific protein-tyrosine kinase; p56-LCK	WB	Human
	Lck Antibody (YA712) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lck.

HY-P810639

	*Phospho-LYN (Tyr397)/LCK* (Tyr394)/HCK (Tyr411)/BLK (Tyr389) Antibody (YA9901)** LYN; JTK8; Tyrosine-protein kinase Lyn; LCK/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB, ICC/IF	Human, Mouse, Rat
	Phospho-LYN (Tyr397)/LCK (Tyr394)/HCK (Tyr411)/BLK (Tyr389) Antibody (YA9901) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-LYN (Tyr397)/LCK (Tyr394)/HCK (Tyr411)/BLK (Tyr389).

HY-P85877

	Lyn Antibody (YA5569) Tyrosine-protein kinase Lyn; LCK/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn;	WB, ICC/IF, ELISA	Human, Mouse, Rat
	Lyn Antibody (YA5569) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lyn.

HY-P80747

	Lyn Antibody (YA707) LYN; JTK8; Tyrosine-protein kinase Lyn; LCK/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB	Human
	Lyn Antibody (YA707) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lyn.

HY-P85265

	Lyn Antibody (YA4957) LYN; JTK8; Tyrosine-protein kinase Lyn; LCK/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB, FC	Human
	Lyn Antibody (YA4957) is a Rabbit-derived and non-conjugated recomninant monoclonal antibody, targeting to Lyn.

HY-P80747A

	Lyn Antibody (YA707)(PBS only) LYN; JTK8; Tyrosine-protein kinase Lyn; LCK/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB	Human
	Lyn Antibody (YA707) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Lyn.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15764G

A 419259 RK-20449	Src Apoptosis	Cancer
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC₅₀s of 9 nM, <3 nM, and <3 nM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LCK

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

GMP Molecules

Natural
Products